Therapy with voretigene neparvovec. How to measure success?. (January 2023)

• Record Type: Journal Article
• Authors: Stingl, Krunoslav; Kempf, Melanie; Jung, Ronja; Kortüm, Friederike; Righetti, Giulia; Reith, Milda; Dimopoulos, Spyridon; Ott, Saskia; Kohl, Susanne; Stingl, Katarina
• Is Part Of: Progress in retinal and eye research. Volume 92(2023)
• Publication Date: 2023-01
• Subjects: Gene therapy -- Safety -- Efficacy -- Retinal functional diagnostics -- Retinitis pigmentosa -- RPE65; Retina -- Periodicals; Retina -- Research -- Methodology -- Periodicals; Eye -- Diseases -- Periodicals; Eye -- Periodicals; Eye Diseases -- Periodicals; Retina -- Periodicals; Rétine -- Périodiques; Rétine -- Recherche -- Méthodologie -- Périodiques; 617.7005
• DOI: 10.1016/j.preteyeres.2022.101115
• Languages: English
• ISSNs: 1350-9462

Abstract

Abstract: Retinal gene supplementation therapy such as the first approved one, voretigene neparvovec, delivers a functioning copy of the missing gene enabling the protein transcription in retinal cells and restore visual functions. After gene supplementation for the genetic defect, a complex network of functional regeneration is the consequence, whereas the extent is very individualized. Diagnostic and functional testings that have been used routinely by ophthalmologists so far to define the correct diagnosis, cannot be applied in the new context of defining small, sometimes subtle changes in visual functions. New view on retinal diagnostics is needed to understand this processes that define safety and efficacy of the treatment. Not only does vision have many aspects that must be addressed by specific evaluations and imaging techniques, but objective readouts of local retinal function for rods and cones separately have been an unmet need until recently. A reliable test-retest variability is necessary in rare diseases such as inherited retinal dystrophies, because statistics are often not applicable due to a low number of participants. Methods for a reliable individual evaluation of the therapy success are needed. In this manuscript we present an elaboration on retinal diagnostics combining psychophysics (eg. full-field stimulus threshold or dark adapted perimetry) as well as objective measures for local retinal function (eg. photopic and scotopic chromatic pupil campimetry) and retinal imaging for a meaningful workflow to apply in evaluation of the individual success in patients receiving gene therapy for photoreceptor diseases. Graphical abstract: Image 1 Highlights: Psychophysics cannot address all aspects of RPE65 gene therapy. Novel functional diagnostics and imaging enables better insight on treatment. For future therapy improvement tailored functional diagnostics is needed.